Drug Screening for Huntington's Disease and Other Neurodegenerative Disorders

Current Molecular Pharmacology

Volumn 3, Issue 3, 2010, Pages 164-173

  Varma, Hemant ^a  

^a Howard Hughes Medical Institute   (United States)

Author keywords

Drug discovery; Huntington's disease; Models; Polyglutamine disease; Screening; Therapy

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACIVICIN; ALPHA SYNUCLEIN; ATAXIN 1; BRAIN DERIVED NEUROTROPHIC FACTOR; CAFFEIC ACID PHENETHYL ESTER; CANNABINOID DERIVATIVE; CARDIAC GLYCOSIDE; CASPASE; CEFTRIAXONE; ESCULETIN; FIBROBLAST GROWTH FACTOR 2; FOSFOSAL; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; HUNTINGTIN; ISOPRENALINE; LITHIUM; MAMMALIAN TARGET OF RAPAMYCIN; MITHRAMYCIN; MUTANT PROTEIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NADOLOL; POLYGLUTAMINE; RILMENIDINE; SODIUM GLUCOSE COTRANSPORTER 1; SOMATOMEDIN C;

ALZHEIMER DISEASE; AMINO ACID TRANSPORT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTOPHAGY; BLOOD BRAIN BARRIER; CELL DEATH; COMPETITIVE INHIBITION; DEGENERATIVE DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SCREENING; DRUG TOLERABILITY; ENZYME ACTIVITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 78650003031     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211003030164     Document Type: Article

References (94)

1. Roberson, E.D.; Mucke, L. 100 years and counting: prospects for defeating Alzheimer's disease. Science (New York, N.Y.), 2006, 314(5800), 781-784.
2. Lansbury, P.T.; Lashuel, H.A. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature, 2006, 443(7113), 774-779.
3. Gatchel, J.R.; Zoghbi, H. Diseases of unstable repeat expansion: mechanisms and common principles. Nat. Rev. Genet. 2005, 6(10), 743-755.
4. Di Prospero, N.A.; Fischbeck, K.H. Therapeutics development for triplet repeat expansion diseases. Nat. Rev. Genet. 2005, 6(10), 756-765.
5. Brunner, D.; Nestler, E.; Leahy, E. In need of high-throughput behavioral systems. Drug discov. today, 2002, 7(18), S107-112.
6. Voisine, C.; Varma, H.; Walker, N.; Bates, E.A.; Stockwell, B.R.; Hart, A.C. Identification of Potential Therapeutic Drugs for Huntington's Disease using Caenorhabditis elegans. PLoS One, 2007, 2, e504.
7. Ferrante, R.J.; Andreassen, O.A.; Dedeoglu, A.; Ferrante, K.L.; Jenkins, B.G.; Hersch, S.M.; Beal, M.F. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci., 2002, 22(5), 1592-1599.
8. Benson, J.D.; Chen, Y.N.; Cornell-Kennon, S.A.; Dorsch, M.; Kim, S.; Leszczyniecka, M.; Sellers, W.R.; Lengauer, C. Validating cancer drug targets. Nature, 2006, 441(7092), 451-456.
9. Smith, A. Screening for drug discovery: the leading question. Nature, 2002, 418(6896), 453-459.
10. Olanow, C.W.; Kieburtz, K.; Schapira, A.H. Why have we failed to achieve neuroprotection in Parkinson's disease? Ann. Neurol., 2008, 64, S101-110.
11. Sipione, S.; Cattaneo, E., Modeling Huntington's disease in cells, flies, and mice. Mol. Neurobiol., 2001, 23(1), 21-51.
12. Frank, S.; Clavaguera, F.; Tolnay, M. Tauopathy models and human neuropathology: similarities and differences. Acta Neuropathol., 2008, 115(1), 39-53.
13. Burdine, L.; Kodadek, T. Target identification in chemical genetics: the (often) missing link. Chem. Biol., 2004, 11(5), 593-597.
14. Graham, R.K.; Deng, Y.; Slow, E.J.; Haigh, B.; Bissada, N.; Lu, G.; Pearson, J.; Shehadeh, J.; Bertram, L.; Murphy, Z.; Warby, S.C.; Doty, C.N.; Roy, S.; Wellington, C.L.; Leavitt, B.R.; Raymond, L.A.; Nicholson, D.W.; Hayden, M.R. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell, 2006, 125(6), 1179-1191.
15. Gu, X.; Greiner, E.R.; Mishra, R.; Kodali, R.; Osmand, A.; Finkbeiner, S.; Steffan, J.S.; Thompson, L.M.; Wetzel, R.; Yang, X.W. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron, 2009, 64(6), 828-840.
16. Ona, V.O.; Li, M.; Vonsattel, J.P.; Andrews, L.J.; Khan, S.Q.; Chung, W.M.; Frey, A.S.; Menon, A.S.; Li, X.J.; Stieg, P.E.; Yuan, J.; Penney, J.B.; Young, A.B.; Cha, J.H.; Friedlander, R.M. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature, 1999, 399(6733), 263-267.
17. Abbott, A. Neurologists strike gold in drug screen effort. Nature, 2002, 417(6885), 109.
18. Hopkins, A.L.; Groom, C.R. The druggable genome. Nat. Rrev. Drug Discov., 2002, 1(9), 727-730.
19. Zuckermann, R.N.; Kodadek, T. Peptoids as potential therapeutics. Curr. Opin Mol. Ther., 2009, 11(3), 299-307.
20. Schreiber, S.L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science (New York, N.Y.), 2000, 287(5460), 1964-1969.
21. Huwe, C.M. Synthetic library design. Drug discov. Today, 2006, 11(15-16), 763-767.
22. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70(3), 461-477.
23. Koehn, F.E.; Carter, G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov., 2005, 4(3), 206-220.
24. Irwin, J.J. How good is your screening library? Curr. Opin. Chem. Biol., 2006, 10(4), 352-356.
25. Walters, W.P.; Namchuk, M. Designing screens: how to make your hits a hit. Nat. Rev. Drug Discov., 2003, 2(4), 259-266.
26. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46(1-3), 3-26.
27. Gimâenez, B.G.; Santos, M.S.; Ferrarini, M.; Fernandes, J.P. Evaluation of blockbuster drugs under the rule-of-five. Die. Pharmazie., 2010, 65(2), 148-152.
28. Mensch, J.; Oyarzabal, J.; Mackie, C.; Augustijns, P. In vivo, in vitro and in silico methods for small molecule transfer across the BBB. J. Pharm. Sci. 2009, 98(12), 4429-4468.
29. Zhang, J., Chung, T.D.; Oldenburg, K.R. A simple statistical parameter for use in evaluation and validation for high throughput screening Assays. J. Biomol. Screen., 1999, 4, 67-83.
30. Tobin, A.J.; Signer, E.R. Huntington's disease: the challenge for cell biologists. Trends Cell Biol., 2000, 10(12), 531-536.
31. Chen, M.; Ona, V.O.; Li, M.; Ferrante, R.J.; Fink, K.B.; Zhu, S.; Bian, J.; Guo, L.; Farrell, L.A.; Hersch, S.M.; Hobbs, W.; Vonsattel, J.P.; Cha, J.H.; Friedlander, R.M. Minocycline inhibits caspase- 1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med., 2000, 6(7), 797-801.
32. Wellington, C.L.; Ellerby, L.M.; Gutekunst, C.A.; Rogers, D.; Warby, S.; Graham, R.K.; Loubser, O.; van Raamsdonk, J.; Singaraja, R.; Yang, Y.Z.; Gafni, J.; Bredesen, D.; Hersch, S.M.; Leavitt, B.R.; Roy, S.; Nicholson, D.W.; Hayden, M.R. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci., 2002, 22(18), 7862-7872.
33. Sarkar, S.; Perlstein, E.O.; Imarisio, S.; Pineau, S.; Cordenier, A.; Maglathlin, R.L.; Webster, J.A.; Lewis, T.A.; O'Kane C. J.; Schreiber, S.L.; Rubinsztein, D.C. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. Chem. Biol., 2007, 3(6), 331-338.
34. Coufal, M.; Maxwell, M.M.; Russel, D.E.; Amore, A.M.; Altmann, S.M.; Hollingsworth, Z.R.; Young, A.B.; Housman, D.E.; Kazantsev, A.G. Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments. J. Biomol. Screen., 2007, 12(3), 351-60.
35. Rigamonti, D.; Bolognini, D.; Mutti, C.; Zuccato, C.; Tartari, M.; Sola, F.; Valenza, M.; Kazantsev, A.G.; Cattaneo, E. Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators. J. Biol. Chem., 2007, 282(34), 24554-24562.
36. Pollitt, S.K.; Pallos, J.; Shao, J.; Desai, U.A.; Ma, A.A.; Thompson, L.M.; Marsh, J.L.; Diamond, M.I. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron, 2003, 40(4), 685-694.
37. Desai, U.A.; Pallos, J.; Ma, A.A.; Stockwell, B.R.; Thompson, L.M.; Marsh, J.L.; Diamond, M.I. Biologically active molecules that reduce polyglutamine aggregation and toxicity. Hum. Mol. Genet., 2006, 15(13), 2114-2124.
38. Piccioni, F.; Roman, B.R.; Fischbeck, K.H.; Taylor, J.P. A screen for drugs that protect against the cytotoxicity of polyglutamineexpanded androgen receptor. Hum. Mol. Genet., 2004, 13(4), 437-446.
39. Wang, W.; Duan, W.; Igarashi, S.; Morita, H.; Nakamura, M.; Ross, C.A. Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model. Neurobiol. Dis., 2005, 20(2), 500-508.
40. Aiken, C.T.; Tobin, A.J.; Schweitzer, E.S. A cell-based screen for drugs to treat Huntington's disease. Neurobiol. Dis., 2004, 16(3), 546-555.
41. Varma, H.; Cheng, R.; Voisine, C.; Hart, A.C.; Stockwell, B.R. Inhibitors of metabolism rescue cell death in Huntington's disease models. Proc. Natl. Acad. Sci. USA,2007, 104(36), 14525-14530.
42. Varma, H.; Voisine, C.; DeMarco, C.T.; Cattaneo, E.; Lo, D.C.; Hart, A.C.; Stockwell, B.R. Selective inhibitors of death in mutant huntingtin cells. Nat. Chem. Biol., 2007, 3(2), 99-100.
43. Barber, S.C.; Higginbottom, A.; Mead, R.J.; Barber, S.; Shaw, P.J. An in vitro screening cascade to identify neuroprotective antioxidants in ALS. Free Radic. Biol. Med., 2009, 46(8), 1127-1138.
44. Rothstein, J.D.; Patel, S.; Regan, M.R.; Haenggeli, C.; Huang, Y.H.; Bergles, D.E.; Jin, L.; Dykes Hoberg, M.; Vidensky, S.; Chung, D.S.; Toan, S.V.; Bruijn, L.I.; Su, Z.Z.; Gupta, P.; Fisher, P.B. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 2005, 433(7021), 73-77.
45. Rubinsztein, D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature, 2006, 443(7113), 780-786.
46. Yamamoto, A.; Cremona, M.L.; Rothman, J.E. Autophagymediated clearance of huntingtin aggregates triggered by the insulin- signaling pathway. J. Cell Biol., 2006, 172(5), 719-731.
47. Menzies, F.M.; Ravikumar, B.; Rubinsztein, D.C. Protective roles for induction of autophagy in multiple proteinopathies. Autophagy, 2006, 2(3), 224-225.
48. Petersâen, A.; Larsen, K.E.; Behr, G.G.; Romero, N.; Przedborski, S.; Brundin, P.; Sulzer, D. Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. Hum. Mol. Genet,. 2001, 10(12), 1243-1254.
49. Jeong, H.; Then, F.; Melia, T.J. Jr.; Mazzulli, J.R.; Cui, L.; Savas, J.N.; Voisine, C.; Paganetti, P.; Tanese, N.; Hart, A.C.; Yamamoto, A.; Krainc, D. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell, 2009, 137(1), 60-72.
50. Wang, T.; Lao, U.; Edgar, B.A. TOR-mediated autophagy regulates cell death in Drosophila neurodegenerative disease. J. Cell Biol., 2009, 186(5), 703-711.
51. Raught, B.; Gingras, A.C.; Sonenberg, N. The target of rapamycin (TOR) proteins. Proc. Natl. Acad. Sci. USA, 2001, 98(13), 7037-7044.
52. Yamamoto, A.; Lucas, J.J.; Hen, R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell, 2000, 101(1), 57-66.
53. Rigamonti, D.; Bauer, J.H.; De-Fraja, C.; Conti, L.; Sipione, S.; Sciorati, C.; Clementi, E.; Hackam, A.; Hayden, M.R.; Li, Y.; Cooper, J.K.; Ross, C.A.; Govoni, S.; Vincenz, C.; Cattaneo, E. Wild-type huntingtin protects from apoptosis upstream of caspase- 3. J. Neurosci., 2000, 20(10), 3705-3713.
54. Jin, K.; LaFevre-Bernt, M.; Sun, Y.; Chen, S.; Gafni, J.; Crippen, D.; Logvinova, A.; Ross, C.A.; Greenberg, D.A.; Ellerby, L.M. FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA, 2005, 102(50), 18189-18194.
55. Saudou, F.; Finkbeiner, S.; Devys, D.; Greenberg, M.E., Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell, 1998, 95(1), 55-66.
56. Zuccato, C.; Ciammola, A.; Rigamonti, D.; Leavitt, B.R.; Goffredo, D.; Conti, L.; McDonald, M.E.; Friedlander, R.M.; Silani, V.; Hayden, M.R.; Timmusk, T.; Sipione, S.; Cattaneo, E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (New York, N.Y.,) 2001, 293(5529), 493-498.
57. Zuccato, C.; Liber, D.; Ramos, C.; Tarditi, A.; Rigamonti, D.; Tartari, M.; Valenza, M.; Cattaneo, E. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol. Res., 2005, 52(2), 133-139.
58. Vogel, S.S.; Thaler, C.; Koushik, S.V. Fanciful FRET. Sci. STKE, 2006, 2006(331), re2.
59. Li, M.; Huang, Y.; Ma, A. A.; Lin, E.; Diamond, M.I. Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice. Neurobiol. Dis., 2009, 36(3), 413-420.
60. Bauer, P.O.; Nukina, N. Enhanced degradation of mutant huntingtin by rho kinase inhibition is mediated through activation of proteasome and macroautophagy. Autophagy, 2009, 5(5), 747-748.
61. Shao, J.; Welch, W.J.; Diprospero, N.A.; Diamond, M.I. Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol. Cell Biol., 2008, 28(17), 5196-5208.
62. Bodner, R.A.; Outeiro, T.F.; Altmann, S.; Maxwell, M.M.; Cho, S.H.; Hyman, B.T.; McLean, P.J.; Young, A.B.; Housman, D.E.; Kazantsev, A.G. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc. Natl. Acad. Sci. USA, 2006, 103(11), 4246-4251.
63. Hickey, M.A.; Chesselet, M.F. Apoptosis in Huntington's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27(2), 255-265.
64. Sanchez Mejia, R.O.; Friedlander, R.M. Caspases in Huntington's disease. Neuroscientist 2001, 7(6), 480-489.
65. Jung, J.; Xu, K.; Lessing, D.; Bonini, N.M. Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3. Hum. Mol. Genet., 2009, 18(24), 4843-4852.
66. Young, J.E.; Gouw, L.; Propp, S.; Sopher, B.L.; Taylor, J.; Lin, A.; Hermel, E.; Logvinova, A.; Chen, S.F.; Chen, S.; Bredesen, D.E.; Truant, R.; Ptacek, L.J.; La Spada, A.R.; Ellerby, L.M. Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation. J. Biol. Chem., 2007, 282(41), 30150-30160.
67. Huynh, D.P.; Yang, H.T.; Vakharia, H.; Nguyen, D.; Pulst, S.M. Expansion of the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi complex and causes cell death. Hum. Mol. Genet., 2003, 12(13), 1485-1496.
68. Aiken, C.T.; Steffan, J.S.; Guerrero, C.M.; Khashwji, H.; Lukacsovich, T.; Simmons, D.; Purcell, J.M.; Menhaji, K.; Zhu, Y.Z.; Green, K.; Laferla, F.; Huang, L.; Thompson, L.M.; Marsh, J.L. Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J. Biol. Chem., 2009, 284(43), 29427-29436.
69. Thompson, L.M.; Aiken, C.T.; Kaltenbach, L.S.; Agrawal, N.; Illes, K.; Khoshnan, A.; Martinez-Vincente, M.; Arrasate, M.; O'Rourke, J.G.; Khashwji, H.; Lukacsovich, T.; Zhu, Y.Z.; Lau, A.L.; Massey, A.; Hayden, M.R.; Zeitlin, S.O.; Finkbeiner, S.; Green, K.N.; LaFerla, F.M.; Bates, G.; Huang, L.; Patterson, P.H.; Lo, D. C.; Cuervo, A.M.; Marsh, J.L.; Steffan, J.S. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J. Cell Biol., 2009, 187(7), 1083-1099.
70. Emamian, E.S.; Kaytor, M.D.; Duvick, L.A.; Zu, T.; Tousey, S.K.; Zoghbi, H.Y.; Clark, H.B.; Orr, H.T. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron, 2003, 38(3), 375-387.
71. Kaytor, M.D.; Byam, C.E.; Tousey, S.K.; Stevens, S.D.; Zoghbi, H.Y.; Orr, H.T. A cell-based screen for modulators of ataxin-1 phosphorylation. Hum. Mol. Genet., 2005, 14(8), 1095-1105.
72. Brandt, R.; Hundelt, M.; Shahani, N. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim. Biophys. Acta, 2005, 1739(2-3), 331-354.
73. Humbert, S.; Bryson, E.A.; Cordeliáeres, F.P.; Connors, N.C.; Datta, S.R.; Finkbeiner, S.; Greenberg, M.E.; Saudou, F. The IGF- 1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell, 2002, 2(6), 831-837.
74. Williams, A.; Sarkar, S.; Cuddon, P.; Ttofi, E.K.; Saiki, S.; Siddiqi, F.H.; Jahreiss, L.; Fleming, A.; Pask, D.; Goldsmith, P.; O'Kane, C.J.; Floto, R.A.; Rubinsztein, D.C. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat. Chem. Biol., 2008, 4(5), 295-305.
75. Rose, C.; Menzies, M.F.; Renna, M.; Acevedo-Arozena, A.; Corrochano, S.; Sadiq, O.; Brown, S.D.; Rubinsztein, D.C. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum. Mol. Genet., 2010, 19(11), 2144-53.
76. Su, B.; Wang, X.; Zheng, L.; Perry, G.; Smith, M.A.; Zhu, X. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim. Biophys. Acta, 2010, 1802(1), 135-142.
77. Mattson, M.P. Calcium and neurodegeneration. Aging Cell, 2007, 6(3), 337-350.
78. Greene, J.G.; Greenamyre, J.T.; Dingledine, R. Sequential and concerted gene expression changes in a chronic in vitro model of parkinsonism. Neuroscience, 2008, 152(1), 198-207.
79. Zhang, Y.; James, M.; Middleton, F.A.; Davis, R.L. Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. American journal of medical genetics. Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics 2005, 137B(1), 5-16.
80. Ross, C.A. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron, 2002, 35(5), 819-822.
81. Van Damme, P.; Robberecht, W. Recent advances in motor neuron disease. Curr. Opin. Neurol., 2009, 22(5), 486-492.
82. Miao, L.; St Clair, D.K. Regulation of superoxide dismutase genes: implications in disease. Free Radic. Biol. Med., 2009, 47(4), 344-356.
83. Vucic, S.; Kiernan, M.C. Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Curr. Mol. Med., 2009, 9(3), 255-272.
84. Sundstrom, L.; Morrison, B.; Bradley, M.; Pringle, A. Organotypic cultures as tools for functional screening in the CNS. Drug discov. Today, 2005, 10(14), 993-1000.
85. Estrada Sâanchez, A.M.; Mejâia-Toiber, J.; Massieu, L. Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch. Med. Res., 2008, 39(3), 265-276.
86. Greenwood, S.M.; Connolly, C.N. Dendritic and mitochondrial changes during glutamate excitotoxicity. Neuropharmacology, 2007, 53(8), 891-898.
87. Marsh, J.L.; Lukacsovich, T.; Thompson, L.M. Animal models of polyglutamine diseases and therapeutic approaches. J. Biol. Chem., 2009, 284(12), 7431-7435.
88. Steffan, J.S.; Bodai, L.; Pallos, J.; Poelman, M.; McCampbell, A.; Apostol, B.L.; Kazantsev, A.; Schmidt, E.; Zhu, Y.Z.; Greenwald, M.; Kurokawa, R.; Housman, D.E.; Jackson, G.R.; Marsh, J.L.; Thompson, L.M. Histone deacetylase inhibitors arrest polyglutamine- dependent neurodegeneration in Drosophila. Nature, 2001, 413(6857), 739-743.
89. Gardian, G.; Browne, S.E.; Choi, D.K.; Klivenyi, P.; Gregorio, J.; Kubilus, J.K.; Ryu, H.; Langley, B.; Ratan, R.R.; Ferrante, R.J.; Beal, M.F. Neuroprotective effects of phenylbutyrate in the N171- 82Q transgenic mouse model of Huntington's disease. J. Biol. Chem., 2005, 280(1), 556-563.
90. Schiffer, N.W.; Broadley, S.A.; Hirschberger, T.; Tavan, P.; Kretzschmar, H.A.; Giese, A.; Haass, C.; Hartl, F.U.; Schmid, B. Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish model. J. Biol. Chem., 2007, 282(12), 9195-9203.
91. Wang, J.; Gines, S.; MacDonald, M.E.; Gusella, J.F. Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. BMC Neurosci., 2005, 6(1), 1.
92. Muegge, I. Selection criteria for drug-like compounds. Med. Res. Rev., 2003, 23(3), 302-321.
93. Cheng, K.C.; Korfmacher, W.A.; White, R.E.; Njoroge, F.G. Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/ Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034. Perspect. Med. Chem., 2008, 1, 1-9.
94. Rester, U. From virtuality to reality - Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective. Curr. Opin. Drug Discov. Dev., 2008, 11(4), 559-568.